Which has grown faster, RXRX or UFPT?

Over the past five years, RXRX grew revenue faster — RXRX at a 45.50% CAGR versus UFPT at 27.47%.

Is RXRX or UFPT more profitable?

UFPT runs the higher net margin — RXRX at -945.92% versus UFPT at 11.45%.

How have RXRX and UFPT total returns compared?

Over the past 5 years, RXRX delivered -25.86% and UFPT delivered 37.11% annualized total return. Past performance doesn't predict future results.

Recursion Pharmaceuticals, Inc. (RXRX) vs UFP Technologies, Inc. (UFPT)

A side-by-side comparison of Recursion Pharmaceuticals, Inc. and UFP Technologies, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

RXRX

Recursion Pharmaceuticals, Inc.

$2.43B

$4.63HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

UFPT

UFP Technologies, Inc.

$2.34B

$302.87HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — RXRX vs UFPT

growth of $100 · dividends reinvested · last 5y

RXRX -73.4% (-23.3%/yr)UFPT +515.4% (+43.8%/yr)UFPT compounded faster over this window

Log scale — wide-divergence pair

RXRX UFPT

RXRX vs UFPT: by the numbers

•RXRX is the larger company ($2.43B vs $2.34B market cap).
•UFPT is profitable (11.45% net margin) while RXRX runs a net loss (-945.92%).
•RXRX grew revenue faster over the past five years (45.50% vs 27.47% CAGR).

Metrics side by side

Valuation

Metric	RXRX	UFPT
P/E ratio	N/A	32.67
Forward P/E	N/A	31.09
PEG ratio	N/A	0.87
P/S ratio	44.29	3.71
P/B ratio	2.65	5.07
EV / EBITDA	N/A	20.54
FCF yield	N/A	2.62%

Profitability

Metric	RXRX	UFPT
Gross margin	-61.96%	28.50%
Operating margin	-867.87%	15.25%
Net margin	-945.92%	11.45%
ROE	-56.71%	15.63%
ROIC	-49.78%	12.75%

Growth (annualized)

Metric	RXRX	UFPT
Revenue CAGR (5Y)	45.50%	27.47%
EPS CAGR (5Y)	N/A	37.73%
FCF CAGR (5Y)	N/A	26.87%
Total return CAGR (5Y)	-25.86%	37.11%

Frequently asked

Which has grown faster, RXRX or UFPT?: Over the past five years, RXRX grew revenue faster — RXRX at a 45.50% CAGR versus UFPT at 27.47%.
Is RXRX or UFPT more profitable?: UFPT runs the higher net margin — RXRX at -945.92% versus UFPT at 11.45%.
How have RXRX and UFPT total returns compared?: Over the past 5 years, RXRX delivered -25.86% and UFPT delivered 37.11% annualized total return. Past performance doesn't predict future results.

Go deeper

Full RXRX analysis Full UFPT analysis Interactive comparison tool

Dig into the metrics

UFP Technologies P/E ratio Recursion Pharmaceuticals ROE UFP Technologies ROE Recursion Pharmaceuticals operating margin UFP Technologies operating margin Recursion Pharmaceuticals revenue growth UFP Technologies revenue growth Recursion Pharmaceuticals free cash flow UFP Technologies free cash flow

Recursion Pharmaceuticals & UFP Technologies appear in these rankings

Fastest Revenue Growth Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.